The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Endothelin and endothelin antagonists in chronic kidney disease
Open accessAbstract
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension accounting for the majority of cases, is on the rise, with up to 160 million individuals worldwide predicted to be affected by 2020. Given that current treatment options, primarily targeted at the renin angiotensin system, only modestly slow down progression to end-stage renal disease, the urgent need for additional effective therapeutics is evident. Endothelin-1 (ET-1), largely through activation of endothelin A receptors, has been strongly implicated in renal cell injury, proteinuria, inflammation and fibrosis leading to CKD. Endothelin receptor antagonists (ERAs) have been demonstrated to ameliorate or even reverse renal injury and/or fibrosis in experimental models of CKD, while clinical trials indicate a substantial antiproteinuric effect of ERAs in diabetic and non-diabetic CKD patients even on top of maximal renin angiotensin system blockade. This review summarizes the role of ET in CKD pathogenesis and discusses the potential therapeutic benefit of targeting the ET system in CKD, with attention to the risks and benefits of such an approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Chronic kidney disease: the global challenge
El Nahas, A. M., & Bello, A. K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17789-7 · Cited by 1,195
Evolving importance of kidney disease: from subspecialty to global health burden
Eckardt, K.-U., Coresh, J., Devuyst, O., Johnson, R. J., Köttgen, A., Levey, A. S., & Levin, A. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60439-0 · Cited by 1,159
Hartleben, B., Gödel, M., Meyer-Schwesinger, C., Liu, S., Ulrich, T., Köbler, S., Wiech, T., Grahammer, F., Arnold, S. J., Lindenmeyer, M. T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39492 · Cited by 721
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Regulation of Blood Pressure and Salt Homeostasis by Endothelin
Kohan, D. E., Rossi, N. F., Inscho, E. W., & Pollock, D. M. (2011) · Physiological Reviews · doi:10.1152/physrev.00060.2009 · Cited by 433
Self-citationHocher, B., Thöne-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V, Siegmund, F., Quertermous, T., Bauer, C., Neumayer, H. H., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119297 · Cited by 409
Endothelins in the normal and diseased kidney
Kohan, D. E. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90004-4 · Cited by 354
Self-citationMahajan, A., Simoni, J., Sheather, S. J., Broglio, K. R., Rajab, M. H., & Wesson, D. E. (2010) · Kidney International · doi:10.1038/ki.2010.129 · Cited by 339
Barton, M., & Yanagisawa, M. (2008) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y08-059 · Cited by 305
Self-citation
Cited by
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Renal tubule injury: a driving force toward chronic kidney disease
Liu, B.-C., Tang, T.-T., Lv, L.-L., & Lan, H.-Y. (2018) · Kidney International · doi:10.1016/j.kint.2017.09.033 · Cited by 913
Atrasentan in Patients with IgA Nephropathy
Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409415 · Cited by 142
Self-citationCheung, C. K., & Mariani, L. H. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.003 · Cited by 2
Metadata
- Authors
- Kohan, D. E., & Barton, M.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 86
- Issue
- 5
- Pages
- 896-904
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1991210746
- Cited by
- 307
- References
- 58
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endothelin and endothelin antagonists in chronic kidney disease. https://app.cochat.ai/papers/10.1038/ki.2014.143
- The paper
- Kohan, D. E., & Barton, M. (2014). Endothelin and endothelin antagonists in chronic kidney disease. Kidney International. https://doi.org/10.1038/ki.2014.143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
